Korean Medication Algorithm for Bipolar Disorder 2018 : Children and Adolescents
- Author:
Se Hoon SHIM
1
;
Won Myong BAHK
;
Bo Hyun YOON
;
Duk In JON
;
Jeong Seok SEO
;
Won KIM
;
Jung Goo LEE
;
Young Sup WOO
;
Jong Hyun JEONG
;
Moon Doo KIM
;
Inki SOHN
;
Hoo Rim SONG
;
Kyung Joon MIN
Author Information
1. Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University, Cheonan, Korea.
- Publication Type:Original Article
- Keywords:
Bipolar disorder;
Children and adolescents;
Pharmacotherapy;
KMAP-BP 2018
- MeSH:
Adolescent;
Antipsychotic Agents;
Aripiprazole;
Bipolar Disorder;
Child;
Drug Therapy;
Humans;
Lithium;
Quetiapine Fumarate;
Risperidone;
Valproic Acid
- From:
Mood and Emotion
2018;16(3):109-122
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2014: Children and Adolescents.METHODS: We performed the survey, using a questionnaire comprising 22 questions according to each situation, in children and adolescents with bipolar disorder.RESULTS: First-line pharmacotherapeutic strategies for manic episode in children with bipolar disorder were a combination of mood stabilizer (MS) and an atypical antipsychotics (AAP), monotherapy with an AAP, risperidone, and aripiprazole. Aripiprazole was selected as first-line medication for depressive episode in children with bipolar disorder, and aripiprazole, and risperidone were selected as first-line at high-risk children. First-line pharmacotherapeutic strategies for manic episode in adolescents were a combination of MS and an AAP, monotherapy with an AAP valproate, lithium, risperidone (Treatment of Choice, TOC), aripiprazole, and quetiapine. First-line pharmacotherapeutic strategies for depressive episode in adolescents, were a combination of an atypical antipsychotics and lamotrigine, valproate, aripiprazole (TOC), risperidone, and quetiapine. For depressive episodes in adolescents at high risk for bipolar disorder, valproate, aripiprazole (TOC), and risperidone were selected as first-line medication.CONCLUSION: We expect that the present KMAP-BP 2018-children and adolescents, is useful for clinicians to treat children and adolescents with bipolar disorder.
